Atea Pharmaceuticals is trading 5.14% lower at $5.35, with no clear company-specific catalyst identified for September 23, 2026. - Recent positive developments include successful Phase 3 hepatitis C trial results and a September 15 Morgan Stanley presentation; neither explains the decline. - The broader market is lower, while biotechnology is outperforming.